Rodman & Renshaw

Rodman & Renshaw has published a research report on Alnylam Pharmaceuticals (NASDAQ: ALNY) after the company reported Phase I data for ALN-TTR02 that showed robust knockdown of the transthyretin (TTR) gene. In the report, Rodman & Renshaw writes, "Recall, this trial and the previous Phase...

Rodman & Renshaw maintained its Celgene (NASDAQ: CELG) Market Perform rating and $76 price target in a research report published today on news of published material relevant to IDH1 mutation and AML in the scientific journal Nature. In the report, Rodman & Renshaw stated, "We continue to...

Rodman & Renshaw reiterates its Market Outperform rating on Ventrus Biosciences (NASDAQ: VTUS) and reduces its price target from $25 to $11. Rodman & Renshaw comments, "VTUS announced this morning that its Phase III trial of VEN 309 (iferanserin) in patients with hemorrhoidal disease...

Rodman & Renshaw reiterates its Outperform rating on Onyx Pharmaceuticals (NASDAQ: ONXX) and raises its rice target from $57 to $73. Rodman & Renshaw notes, "The carfilzomib (Kyprolis) ODAC panel voted overwhelmingly in favor of recommending the drug for approval, removing, in our view,...

According to a research report published this morning, Rodman & Renshaw maintains its Outperform on MediciNova (NASDAQ: MNOV) and places its previous $13 price target under review. Rodman & Renshaw mentioned in the report, "On May 23, 2012 MediciNova announced results from its Phase 2b...

Listed below are today's Top Upgrades covered by Benzinga: Stifel Nicolaus Upgrades Boeing Company (NYSE: BA) to Buy: Stifel Nicolaus comments, "The overall market may be weak, but we think there is strength in the aerospace cycle. Boeing management's reaffirmation of build rate increases through...

Rodman & Renshaw upgrades PharmAthene (NYSE: PIP) from Market Perform to Market Outperform and establishes a price target of $7 a share. Rodman & Renshaw notes, "The Delaware Chancery Court issued a Final Judgment with favorable economics to PharmAthene. Therefore, we are upgrading our...

Rodman & Renshaw initiates its coverage of Ducommun (NYSE: DCO) with a Market Perform rating and no price target. Rodman & Renshaw notes, "Recent financial performance has been impacted by a decline in volumes for certain military platforms, new commercial program ramp-up costs and a...

Rodman & Renshaw remains rated Outperform on Quepasa (NYSE: QPSA) and maintains its $7 price target on shares. Rodman & Renshaw notes, "Today,Facebook (FB, Not Rated) is coming out with its own IPO. The company joins a host of other social media / network plays that have come public over...

Rodman & Renshaw initiates its coverage on Superconductor Technologies (NASDAQ: SCON) with a Market Perform rating. Rodman & Renshaw comments, "SCON has spent the last few years in efforts to commercialize the next generation of HTS wires that should find applications in the deployment of...

Rodman & Renshaw raises its price target $2 to $6 on Top Image Systems (NASDAQ: TISA) following recent rally in share prices. Rodman & Renshaw notes, "After a negative initial response to the company's 4Q11 results, which we were surprised by, TISA stock has rallied by over 33% in the...

Rodman & Renshaw lowers its price target to $4 on Outperform-rated Voyager Oil & Gas (NYSE: VOG) to reflect a more conservative view on production growth. Rodman & Renshaw notes, "We're going to take a more conservative approach to the company's Bakken production ramp due to a...

According to a research report published earlier today, Rodman & Renshaw have increased Endeavour International Corporation's (NYSE: END) PT from $15 to $16. “We came away from END's investor day with greater conviction in the story. While the company did not provide much incremental...

According to a research report published earlier today, Rodman & Renshaw has initiated TriMas Corporation (NASDAQ: TRS) with a Market Outperform rating and a $32 PT. Rodman & Renshaw commented in the report, “The company's brands are well positioned in their respective markets. Across its...

Rodman & Renshaw increases its price target $3 to $16 on Outperform-rated Omeros Corporation (NASDAQ: OMER) as pivotal eye data achieves all endpoints. Rodman & Renshaw says, "Today Omeros announced positive data from its Phase 3 clinical trial evaluating its combination drug OMS302 in...